Gresonitamab (Anti-Human CD3xClaudin18 2)

Gresonitamab, also known as AMG 910 is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody that targets CD3 in T cells and Claudin 18 isoform 2 (CLDN18.2) in cancer cells. Gresonitamab is being studied for cancer treatment. Claudins are integral membrane proteins and components of tight junction strands which serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets. The claudin-18 gene has two splice variants: claudin-18.1, which is found primarily in the lung, and claudin-18.2, which is expressed exclusively in the stomach. Claudin-18.2 is highly expressed in gastric and pancreatic adenocarcinoma and may be involved in tumor development and progression. Due to the morphological changes and epithelial-mesenchymal transition occurring upon cancer progression, the extracellular loops of claudin 18.2 become exposed and available for antibody binding. These biological characteristics suggest that it is an ideal target for therapy and have led to the further development of monoclonal antibodies against claudin 18.2, such as Zolbetuximab. BiTEs (bispecific T-cell engagers) are also under consideration, with Gresonitamab currently tested for cancer treatment.